Merck reduced its acquisition offer for Terns Pharmaceuticals from $61 to $53 per share after reviewing updated clinical trial data for TERN-701, showing a lower MMR achievement rate than expected. A competing bidder also withdrew its offer due to concerns about the drug's differentiation and risk profile, though Merck maintained enthusiasm for t...

Merck & Co. shares declined 3.12% on Tuesday amid a broader market downturn, with the S&P 500 down 0.9% and the Healthcare sector down 0.5%. The decline occurred despite positive momentum from Merck's announced acquisition of Terns Pharmaceuticals for $53.00 per share in cash. While technical indicators show bullish signals with strong 12-month g...

Merck announced its acquisition of Terns Pharmaceutical for $6.7 billion to bolster its cancer treatment pipeline with TERN-701, an oral BCR-ABL1 inhibitor for chronic myeloid leukemia. This marks the third multi-billion-dollar acquisition in a year, reinforcing Merck's M&A strategy. The company has a strong earnings track record, forecasts over ...

Merck & Co entered a collaboration with Infinimmune to develop next-generation antibody drugs using Infinimmune's human-first discovery platform and machine learning technology. Under the deal, Merck gains exclusive development and commercial rights to antibody candidates, with Infinimmune eligible to receive up to $838 million in milestone payme...

Merck agreed to acquire Terns Pharmaceuticals for $6.7 billion ($53 per share) to bolster its pipeline ahead of Keytruda's patent expiry in 2028. The deal focuses on Terns' early-stage CML treatment TERN-701. However, analysts suggest the offer may undervalue the asset and could attract competing bids from other pharmaceutical companies.